Cargando…

SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review

AIM OF THE STUDY: To evaluate the efficacy of sodium/glucose cotransporter-2 inhibitors (SGLT2i) in improving hepatic fibrosis and steatosis of non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS: We searched CENTRAL, MEDLINE, and EMBASE and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dwinata, Michael, Putera, David Dwi, Hasan, Irsan, Raharjo, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816633/ https://www.ncbi.nlm.nih.gov/pubmed/33511282 http://dx.doi.org/10.5114/ceh.2020.102173

Ejemplares similares

Carvedilol vs endoscopic variceal ligation for primary and secondary prevention of variceal bleeding: Systematic review and meta-analysis
por: Dwinata, Michael, et al.
Publicado: (2019)

Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease
por: JASIRWAN, Chyntia Olivia Maurine, et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
por: Tuong, Tran Thi Khanh, et al.
Publicado: (2020)

Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
por: Ayoub, Fares, et al.
Publicado: (2018)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
por: David-Silva, Aline, et al.
Publicado: (2020)

Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review
por: Astarini, Fajar Dwi, et al.
Publicado: (2022)

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
por: Raj, Henith, et al.
Publicado: (2019)

Hepatic Fibrosis and Steatosis in Metabolic Syndrome
por: Gangireddy, Venu Gopala Reddy, et al.
Publicado: (2022)

Gentiopicroside Ameliorates the Progression from Hepatic Steatosis to Fibrosis Induced by Chronic Alcohol Intake
por: Yang, Hong-Xu, et al.
Publicado: (2020)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Wei, Qiong, et al.
Publicado: (2021)

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
por: Elhini, Sahar H., et al.
Publicado: (2022)

Hepatic steatosis and fibrosis: Non-invasive assessment
por: Karanjia, Rustam N, et al.
Publicado: (2016)

Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2022)

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
por: Huang, Yan, et al.
Publicado: (2022)

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
por: Mirarchi, Luigi, et al.
Publicado: (2022)

SGLT5 Reabsorbs Fructose in the Kidney but Its Deficiency Paradoxically Exacerbates Hepatic Steatosis Induced by Fructose
por: Fukuzawa, Taku, et al.
Publicado: (2013)

Betaine in ameliorating alcohol-induced hepatic steatosis
por: Rehman, Aisha, et al.
Publicado: (2021)

SGLT2 inhibitors: An answer to diabetes or a question to its complications?
por: Priya, et al.
Publicado: (2022)

OR27-2 Growth Hormone Reduces Hepatic Steatosis, Inflammation and Fibrosis in Adults with Overweight/Obesity and Nonalcoholic Fatty Liver Disease
por: Bartsch, Lea, et al.
Publicado: (2022)

Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
por: Bellanti, Francesco, et al.
Publicado: (2022)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
por: Saad, Ranin, et al.
Publicado: (2022)

Fatty Acid Excess Dysregulates CARF to Initiate the Development of Hepatic Steatosis
por: Hasan, Kamrul M., et al.
Publicado: (2023)

The association of hepatic steatosis and fibrosis with heart failure and mortality
por: Park, Jiyun, et al.
Publicado: (2021)

Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease
por: Veltkamp, Claudia, et al.
Publicado: (2022)

The ultrasound‐guided attenuation parameter is useful in quantification of hepatic steatosis in non‐alcoholic fatty liver disease
por: Ogino, Yu, et al.
Publicado: (2021)

Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density
por: Xie, Ruijie, et al.
Publicado: (2022)

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
por: Akuta, Norio, et al.
Publicado: (2020)

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
por: Lee, Seung Min, et al.
Publicado: (2022)

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
por: Arai, Taeang, et al.
Publicado: (2022)

Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis
por: Lin, Cheng-Jie, et al.
Publicado: (2018)

The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms
por: JASIRWAN, Chyntia Olivia Maurine, et al.
Publicado: (2019)

Disturbances in the murine hepatic circadian clock in alcohol-induced hepatic steatosis
por: Zhou, Peng, et al.
Publicado: (2014)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
por: Hara, Tomoyo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kkuk1ldo6f5bp8pv6sm0o85sa1